17.APRIL 2019 AT 07:00:00 CET Kiadis to Acquire CytoSen Therapeutics, Inc. Transaction creates leader in cell-based cancer immunotherapy, with complementary T-cell and NK-cell platforms focused initially on hematopoietic stem cell transplants (HSCT) CytoSen’s lead NK-cell therapy candidate, CSDT002-NK, is expected to enter clinical development in 2020 building on successful clinical proof-of-concept studies in 25 patients at… Continue reading KIADIS TO ACQUIRE CYTOSEN THERAPEUTICS, INC.
Blog posts
Kiadis Pharma raises €31.2 million in a private placement of 3.9 million new shares
Amsterdam, The Netherlands, October 19, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it has raised gross proceeds of €31.2 million through a private placement of 3.9 million new shares to institutional investors via an accelerated bookbuilding process as announced on… Continue reading Kiadis Pharma raises €31.2 million in a private placement of 3.9 million new shares
KIADIS PHARMA PROVIDES REGULATORY AND CLINICAL UPDATE ON ATIR101
– Potential CHMP opinion moved from Q4 2018 into H1 2019 – Guidance for initial EU commercial launch in H2 2019 unchanged – FDA meeting held under RMAT status – Phase 3 study on track with over 20 open sites expected by end 2018, of which several in US Amsterdam, The Netherlands, October 12, 2018… Continue reading KIADIS PHARMA PROVIDES REGULATORY AND CLINICAL UPDATE ON ATIR101
Kiadis Pharma announces Financial Results for the six months ended June 30, 2018 and Company update
Amsterdam, The Netherlands, August 31, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces its unaudited interim Financial Results for the six months ended June 30, 2018, which have been prepared in accordance with IAS 34 as adopted by the European Union. Arthur… Continue reading Kiadis Pharma announces Financial Results for the six months ended June 30, 2018 and Company update
Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer
Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that Robbert van Heekeren is stepping down as Chief Financial Officer, or CFO, and as member of the Management Board. Scott A. Holmes has been appointed as new CFO.… Continue reading Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer
